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SESSION 1—HEPATIC 
ENCEPHALOPATHY
CONFERENCE 1: GUT-LIVER-BRAIN AXIS 
IN CIRRHOSIS—CHRISTOPHER ROSE
Hepatic encephalopathy (HE) is a debilitating 
complication of cirrhosis characterized by cogni-
tive, psychiatric and motor disturbances. The de-
terioration of brain function due to liver disease 
manifests as a wide spectrum of neurological ab-
normalities ranging from subclinical alterations 
to coma. Its diagnosis requires exclusion of other 
known brain diseases. Onset of HE is associated 
with a higher mortality than other causes of de-
compensation of cirrhosis (1).
Ammonia is the main and most studied pathophys-
iologic factor in HE. Ammonia levels are increased in 
cirrhosis due to spontaneous porto-systemic shunt-
ing and hepatocellular dysfunction. Ammonia, hav-
ing chemical properties similar to potassium, readily 
crosses the blood-brain barrier and cellular mem-
branes and is transformed to glutamine in astro-
cytes, causing swelling and cerebral edema (2) and 
leading to dysfunction of the astrocyte-neuron unit 
and yielding variable levels of cerebral dysfunction. 
Elevated blood ammonia levels are associated with a 
worse prognosis in cirrhotic patients (3). Its toxicity 
on other organs, including skeletal muscle, has also 
been shown to have deleterious effects (4,5).
Other key actors in the pathogenesis of HE in-
clude systemic inflammation and oxidative stress. 
Many studies have highlighted their role as aggra-
vating factors to the neuropsychological effects of 
hyperammonemia (6–8). Another factor that has 
recently generated interest is elevated lactate levels 
at the cerebral level (9).
HE is part of a continuum including covert HE, 
diagnosed only using psychometric tests, and overt 
HE. It is known that patients with covert HE are at 
a higher risk of presenting with overt HE and that 
a first episode of overt HE is associated with a more 
that 50% risk of recurrent HE at 6 months (10,11). 
HE, a metabolic disorder, is assumed to completely 
resolve following liver transplantation. However, 
several studies have reported persisting neurologi-
cal complications in 15–45% of transplanted patients 
(12,13). It is now thought that recurrent HE leads to 
irreversible brain injury via senescence and neuro-
nal cell loss before surgery (14,15). Moreover, liver 
transplantation is a major procedure associated with 
blood loss, hypotension, complex anaesthesia and 
immunosuppressive medication that have worse im-
pacts on a brain frailed by previous exposition to HE.
Because of its significant burden on the qual-
ity of life, functioning of patients and their care-
givers, better identification of patients at risk of 
HE remains an unmet clinical need in patients 
with cirrhosis to implement better preventive 
strategies.
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CONFERENCE 2: PRE-CIRRHOTIC 
COGNITIVE DECLINE—MARK SWAIN
Many cognitive domains can be potentially im-
pacted by liver disease including attention, pro-
cessing speed, executive functions, reaction time, 
working memory and visual-spatial function. 
Dysfunction in one or more of these domains is 
often referred to by patients as “brain fog”.
Hepatic encephalopathy is the most known and 
studied neurological complication of liver disease. 
It is classically associated with cirrhosis. However, 
cerebral dysfunction occurring at earlier stages of 
fibrosis is generally under-studied.
Primary biliary cholangitis (PBC) has been used 
as a model to study pre-cirrhotic cerebral dysfunc-
tion as its diagnosis is based on robust criteria and 
as patients present a high burden of symptoms in-
cluding pruritus, fatigue, depression, but also cog-
nitive dysfunction.
Magnetic resonance imaging (MRI) studies 
have revealed multiple alterations in the central 
nervous system of patients with pre-cirrhotic PBC 
compared with healthy controls:
 – Decreased amplitude of low-frequency fluc-
tuations (ALFF), a sign of spontaneous neural 
activity, of the insula, a region where interocep-
tive signals are integrated with emotional, cog-
nitive and motivational signals.
 – Decrease in the size of the hippocampus, a key 
structure for emotional and cognitive processes, 
a change similar to that in patients with neuro-
logical disorders such as multiple sclerosis and 
Alzheimer’s disease.
 – Increased hippocampal susceptibility as-
sessed by quantitative susceptibility 
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mapping, an indicator of local neuroinflam-
mation (1,2).
 – Alteration in the resting state functional connec-
tivity of neural networks of the deep gray matter 
in patients with non-cirrhotic PBC compared with 
healthy controls and in non-responders to ursode-
oxycholic acid compared with responders (3).
 – Various signalling pathways have been pro-
posed to explain CNS dysfunction in patients 
with non-cirrhotic disease (4):
 – Humoral route through pro-inflammatory 
cytokines
 – Immune route through immune cell activation
 – Systemic inflammation originating in the gut 
through dysbiosis and altered permeability 
leading to increased cytokines, pathogen-asso-
ciated molecular patterns (PAMPs) (5)
Better understanding of the CNS dysfunction 
occurring in pre-cirrhotic patients has the potential 
to improve quality of life and prevention of overt 
hepatic encephalopathy.
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CONFERENCE 3: DIAGNOSIS AND 
MANAGEMENT OF HEPATIC 
ENCEPHALOPATHY—JS BAJAJ
Hepatic encephalopathy (HE) is brain dysfunction 
caused by liver dysfunction and/or porto-systemic 
shunting (Table 1). It manifests as a wide spectrum 
of neurologic and psychiatric abnormalities from 
subtle alterations in psychometric tests to hepatic 
coma (1). HE is an important cause of morbidity in 
cirrhosis, being responsible for many hospital re-
admissions and an important detrimental effect on 
the quality of life of patients and caregivers.
Covert HE is present in 40–60% of patients with 
cirrhosis. It can only be diagnosed using special-
ized testing. It is associated with a higher risk of 
progression to overt HE, worse socio-economic 
status, poorer quality of life, falls and poor driv-
ing skills, death and hospitalizations (2–4). In the 
real-world setting, diagnostic tests include the En-
cephalApp, the SIP questionnaire or the Animal 
naming test (5–7). Current evidenced-based thera-
peutic strategies include lactulose, rifaximin and 
probiotics (8–10).
The management of an acute episode overt 
HE implies confirmation of the diagnosis, protec-
tion of the airway, identification of the precipitat-
ing factor. Common precipitating factors include 
infections, gastro-intestinal bleeding, electrolyte 
abnormalities and dehydration. Clues against the 
diagnosis of HE include new focal deficits, excit-
atory motor activity and intoxication with alcohol 
or sedative drugs. Blood ammonia levels are not 
useful in an individual patient as they do not add 
diagnostic or staging information, unless they are 
normal in which HE is practically excluded. Poly-
ethylene glycol (PEG) has a therapeutic interest in 
patients with high-grade HE (11). At the time of 
discharge, evaluation of the autonomy of the pa-
tient and caregiver education are essential and the 
question of liver transplantation must be brought 
up.
The first-line treatment to prevent HE recurrence 
is lactulose (12). Its use implies patient education 
on dose adjustment, adverse effect management 
and counselling of family members. The second-
line treatment in patients with recurrent HE de-
spite lactulose or who are lactulose-intolerant is 
rifaximin (13). Non-pharmacologic options include 
nutritional therapy with optimal energy intake, no 
dietary protein restriction and frequent meals, in-
cluding a late-night snack, stress reduction therapy 
and physical therapy (14–15).
Canadian Liver Journal Fall 2019     141
Decompensated cirrhosis: from clinic to transplant
covert hepatic encephalopathy without 
specialized tests. Clin Gastroenterol 
Hepatol. 2014;12(8):1384–89.e2. https://
d o i . o r g / 1 0 . 1 0 1 6 / j . c g h . 2 0 1 3 . 1 2 . 0 2 0 . 
Medline:24362049
6. Allampati S, Duarte-Rojo A, Thacker LR, 
Patidar KR, White MB, Klair JS, et al. Diagnosis 
of Minimal Hepatic Encephalopathy 
Using Stroop EncephalApp: A Multicenter 
US-Based, Norm-Based Study. Am J 
Gastroenterol. 2016;111(1):78–86. https://doi.
org/10.1038/ajg.2015.377. Medline:26644276
7. Campagna F, Montagnese S, Ridola L, Senzolo 
M, Schiff S, Rui MD, et al. The animal naming 




8. Prasad S, Dhiman RK, Duseja A, Chawla YK, 
Sharma A, Agarwal R. Lactulose improves 
cognitive functions and health-related 
quality of life in patients with cirrhosis 
who have minimal hepatic encephalopathy. 
Hepatology. 2007;45(3):549–59. https://doi.
org/10.1002/hep.21533. Medline:17326150
9. Sidhu SS, Goyal O, Parker RA, Kishore H, 
Sood A. Rifaximin vs. lactulose in treatment 
of minimal hepatic encephalopathy. Liver Int. 
2016;36(3):378–85. https://doi.org/10.1111/
liv.12921. Medline:26201713
10. Bajaj JS, Saeian K, Christensen KM, 
Hafeezullah M, Varma RR, Franco J, et 
al. Probiotic Yogurt for the Treatment of 




Management of refractory cases includes ruling 
out alternate diagnoses, incorrect diagnosis and 
treatment of precipitating factors, consideration of 
spontaneous porto-systemic shunt embolization and 
participation in research protocols for new options 
such as fecal microbiota transplantation (16–19).
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estimated to be 10 to 15% in compensated cirrhosis 
(1) and given the earlier diagnosis of compensated 
cirrhosis with transient elastography scan, these 
numbers might even be lower. This means that 80 
to 95% of screening endoscopies in compensated 
cirrhosis do not result in a therapeutic action. Stud-
ies have looked at non-invasive tools (NIT) to iden-
tify patients at very low risk of having moderate or 
large-sized varices in which prophylaxis of bleed-
ing is indicated and in whom diagnostic endos-
copy could be avoided.
The ANTICIPATE trial brought data to develop a 
model for the identification of patients with varices 
needing treatment (VNT) (2). In this population of 
518 patients with Child A compensated cirrhosis 
in five centres, non-invasive tests including liver 
stiffness measurement and spleen size assess-
ment were performed, paired with upper gastro-
intestinal endoscopy and hepatic venous pressure 
gradient measurement (HVPG) in some. The com-
bination of liver stiffness, spleen size and platelet 
count performed best at assessing the presence of 
VNT. In this cohort, the criteria proposed in the 
Baveno VI consensus to avoid upper endoscopy, 
platelet count over 150 × 109/L and liver elastogra-
phy below 20 kPa, the predicted risk of VNT was at 
5%. In a subsequent study including new cohorts 
with lower risk of VNT (5%), platelets count above 
110 × 109/L and transient elastography measure-
ment below 25 kPa could spare 32% endoscopies 
with even fewer (1,9%) missed VNT (3). This led 
to the proposed Expanded Baveno VI criteria that 
might work well in settings with very low risk of 
VNT.
However, in patients with non-alcoholic fatty 
liver disease related cirrhosis, those with a body-
mass index (BMI) below 30 and using M Probe, it 
appears that the Baveno VI criteria should be pre-
ferred since the expanded criteria led to an excess 
of 7% missed VNT (4). This same observation has 
been made in cholestatic liver disease population 
(PBC and PSC) with excess of missed VNT using 
expanded Baveno VI criteria (5).
For the prevention of cirrhosis decompensation, 
the use of non-selective beta-blocker (NSBB) was 
ineffective to prevent varices and variceal bleeding 
in patients with portal hypertension (HVPG of 6 
mmHg or more) and no varices at baseline (6). The 
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SESSION 2—BLEEDING AND 
COAGULOPATHY IN CIRRHOSIS
CONFERENCE 4: PRIMARY VARICEAL 
SCREENING: IS ENDOSCOPY 
REQUIRED?—JG ABRALDES
It is known that the identification and prophylac-
tic treatment of high-risk varices can significantly 
reduce the 1-year risk of variceal bleeding. There-
fore, endoscopic screening for esophageal varices 
has become part of the standard of care of cirrhotic 
patient. The prevalence of high-risk varices is 
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placebo for those with acute propranolol response 
or carvedilol or placebo for non-responders. The 
primary endpoint was new cirrhosis decompensa-
tion with a median follow up of 3 years. Liver cir-
rhosis etiology were mostly alcohol and hepatitis 
C and both groups had an average MELD score of 
7. The mean HVPG was also similar at 15 mmHg. 
The use of NSBB allowed to decrease by half the in-
cidence of cirrhosis decompensation at 48 months. 
This result was mainly driven by decreased oc-
currence of ascites, but this strategy did not pre-
vent development of high-risk varices and reduce 
bleeding rates, probably because band ligation was 
performed in those showing high-risk varices (7). 
Therefore, beta-blockers should be considered in 
those with compensated disease and CSPH to pre-
vent decompensation.
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CONFERENCE 5: VARICEAL BLEEDING: 
HOW CAN WE IMPROVE THE 
OUTCOME?—J BISSONNETTE
During upper gastrointestinal bleeding, a restric-
tive hemoglobin (Hb) target transfusion strategy 
of Hb > 70 g/L has been shown to significantly 
decrease 45 day-mortality when compared with a 
liberal target Hb > 90 g/L, including Child-Pugh A 
and B patients (1).
The early (within 2 hours) use of hemostatic pow-
der, in adjunction to usual pharmacotherapy, with 
repeated definitive therapeutic endoscopy within 
12 to 24 hours led to high short-term endoscopic 
hemostasis, as well as an absolute decrease of 23% 
of 6-week mortality compared with standard phar-
macologic and endoscopic management during 
acute variceal bleeding (AVB) in a randomized trial 
(2). This option can be considered in acute variceal 
bleeding for less experienced endoscopists and for 
massive bleeding situations. It also highlights the 
importance of early endoscopic treatment.
Self-expanding esophageal stents (SX-ELLA 
Stent Danis®) have become an interesting alter-
native to balloon tamponade for refractory AVB. 
In a small randomized-controlled trial, its use 
144     Canadian Liver Journal Fall 2019
V Dong, M Gosselin, N Jagarlamudi, et al
significantly decreased the occurrence of deleteri-
ous adverse events and improved hemostasis at 
15 days compared with balloon tamponade. Al-
though not demonstrated in small trials with cir-
rhotic patients, a survival benefit was observed 
in the acute-on-chronic liver failure setting as a 
bridge to transplantation in patients with refrac-
tory bleeding and contra-indication to transjugular 
intrahepatic portosystemic shunt (TIPS) (3,4).
TIPS is commonly indicated in AVB with failure 
of endoscopic treatment and for early rebleeding. 
In an unselected cirrhotic population who under-
went successful early endoscopic hemostasis, TIPS 
was superior to prevent recurrence of bleeding 
at 36 months but did not improve survival and 
was associated with higher rates of early hepatic 
encephalopathy when compared with standard 
management with endoscopic band ligation and 
non-selective beta-blockers (5). Patients with a he-
patic venous pressure gradient (HVPG) during the 
index AVB over 20 mmHg seem to have a survival 
benefit from TIPS (6). This led to the landmark 
trial of early TIPS strategy (7) where a hemostatic 
and survival benefit were observed in Child-Pugh 
B patients with active bleeding at endoscopy and 
Child-Pugh C with 10 to 13 points in which TIPS 
was performed. These results were confirmed in an 
observational non-randomized study when apply-
ing the same inclusion and exclusion criteria (8). In 
another observational study, this survival benefit 
was found in the Child-Pugh C population, but 
not in Child-Pugh B patients with active bleeding 
(9). Two randomized-controlled trial are underway 
in Scotland and China to confirm these results in 
Child > 7 population. In a French multicenter au-
dit, there was no trend in survival benefit using the 
early TIPS strategy in 326 patients eligible over a 
population of 964 patients with portal hyperten-
sion-related bleeding. Early TIPS was performed 
in only 7% of eligible case, primarily because of 
no local availability or lack of belief in beneficial 
effect. This raises the question of applicability of 
such recommendations to real-life practice (10).
General anaesthesia may underestimate the real 
HPVG. In an observational study, the effect of deep 
sedation showed more than 10% difference with 
the awake HPVG (11). After TIPS insertion, fewer 
bleeding and ascites were noticed if the HPVG 
was below 12 mmHg on short-term follow-up (12). 
Hence, TIPS revision can be used prior to discharge.
For post discharge management, simvastatin 
in conjunction with standard medical treatment 
improved survival without reducing rebleeding 
rates in a randomized-controlled trial studying its 
use in secondary prevention (13). In animal mod-
els, this observation is thought to be the effect of 
decreased portal pressure by decreasing portal re-
sistance. The precise role of statins in patients with 
cirrhosis needs further studies. A meta-analysis has 
highlighted the importance of NSBB in improving 
24-month survival in Child-Pugh B/C population 
in adjunction to EVL after variceal bleeding. How-
ever, this improvement in survival has not been 
demonstrated in Child-Pugh A patients (14).
There are two endovascular treatment for gas-
tric variceal bleeding. Namely, balloon-occluded 
retrograde transvenous obliteration (BRTO) and 
TIPS can be considered in this setting. There are 
no comparative studies, but both have hemostatic 
success above 90%. There are lower rates of asci-
tes and rebleeding with a combined technique. 
Because of the opposing effects on the portal he-
modynamics, several factors should be taken in 
consideration: presence of ascites, encephalopathy, 
vascular anatomy, contra-indication to TIPS and 
local experience (15–17).
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anticoagulation for venous thromboembolism, 
but not when compared with matched cirrhotic 
patients not receiving anticoagulation. Therefore, 
the increase in the bleeding risk seems related 
to portal hypertension rather than anticoagula-
tion itself (6). The platelet count threshold of 50 × 
109/L has been identified as a cut-off below which 
the bleeding risk significantly increases with anti-
coagulation (7).
Predictors of spontaneous recanalization have 
not been identified in high-quality studies. Case 
reports have described that the factors that predict 
recanalization are provoked events, non-occlusive 
thrombi and early recanalization (8–10). In cohort 
studies, there was no association found with age, 
thrombus localization, MELD score, Child cat-
egory, decompensation, ascites, variceal bleeding 
or kidney function (11,12). Also, in another cohort 
study, the mean size of largest collateral, by divert-
ing flow from the main portal vein, and portal vein 
flow were negatively associated with spontaneous 
recanalization (13).
For those undergoing anticoagulation, predic-
tors of successful therapy include: recent time of 
onset, early initiation and degree of thrombus bur-
den (14). The recurrence after discontinuing the 
anticoagulation ranges between 27 and 38% (15).
Small studies have suggested effectiveness and 
safety of direct-acting oral anticoagulant in pa-
tients with Child-Pugh A cirrhosis (16–18).
In conclusion, the decision to treat PVT in cir-
rhosis should be individualized and based on 
multiple factors: acuteness, symptomatology, ex-
tension and thrombus burden, bleeding risk and 
liver transplantation candidacy. In contrario, pa-
tients with fully collateralized chronic PVT (carver-
noma) are unlikely to benefit from anticoagulation. 
All these factors have to be balanced in terms of 
risks and benefits. Life expectancy should be taken 
into account, particularly in Child B-C patients 
who is not transplant candidates. Randomized 
controlled trials are needed and outcome should 
include potential risks of treatment versus no treat-
ment. The duration of anticoagulation should be at 
least 6 months with imaging follow-up to assess 
recanalization.
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CONFERENCE 7: COAGULOPATHY IN 
CIRRHOSIS—RT STRAVITZ
The bleeding tendency in patients with liver dis-
ease differs based on the clinical condition, as 
shown in Table 1. Patients with stable cirrhosis 
have mild synthetic failure as demonstrated by 
small increases of the INR, with moderate throm-
bocytopenia secondary to the moderate portal hy-
pertension and minimal systemic inflammation. 
Acute liver failure presents with minimal or no 
portal hypertension and variable levels of systemic 
inflammation, but dramatically increased INR due 
to impaired synthetic function. In acute on chronic 
liver failure (ACLF), portal hypertension, failure 
of liver synthetic function is severe, worse failure 
and thrombocytopenia and important systemic 
inflammation.
As reported by Tripodi (1), conventional coag-
ulation tests such as prothrombin time and acti-
vated partial thromboplastin time are inadequate 
to estimate the global coagulation function of a 











Portal Hypertension ++ −/+ +++
Synthetic Failure / ↑ 
INR
+ +++ +++
Thrombocytopenia ++ + +++
Systemic 
Inflammation
+ + → +++ +++
• Patients with cirrhosis rarely bleed apart from 
complications of portal hypertension.
• When they do bleed, the sites and types of bleed-
ing are different than patients with hereditary or 
acquired factor deficiencies.
• Patients with cirrhosis have an increase ten-
dency to develop thrombosis.
Although it is a powerful prognostic tool in 
acute or chronic liver disease, the INR does not 
predict acute variceal bleeding and its correction 
with recombinant factor VIIa does not improve 
patient outcomes in this setting (2). Also, it does 
not predict bleeding complications after invasive 
procedures in patients with cirrhosis. However, a 
platelet count below 60 × 109/L is associated with 
a higher risk of bleeding complications after liver 
biopsy (3). This threshold is correlated in vitro with 
preserved thrombin generation if the platelet count 
is above 60 × 109/L (4).
In fact, several studies support the fact that stable 
cirrhotic patients are more in a hypercoagulable 
state: increased risk of portal vein thrombosis, in-
creased risk of venous thromboembolism in hos-
pitalized patients and increased risk for ischemic 
stroke when adjusted for risks factors. Levels of von 
Willebrand factor and factor VIII increase with pro-
gression of the liver disease, at least partly due to 
bacterial translocation and gut-derived endotoxin 
(5,6). This leads to an increased factor VIII/protein 
C ratio (7), which tips the balance between procoag-
ulant and anticoagulant factors towards a slightly 
hypercoagulable state despite decreased thrombo-
cytopenia and decreased coagulation factors.
The same observation has been made in patients 
with acute liver failure where bleeding complica-
tions occur at a relatively low incidence despite 
profound derangements in hemostasis tests. The 
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global hemostasis is rebalanced or tipped slightly 
toward hypercoagulability, as shown by throm-
boelastography (8) and thrombin generation (9) 
studies. There is also a compensation for thrombo-
cytopenia with increased vWF levels which lead to 
increased platelet adherence.
In an ACLF cohort, the predictors of major 
bleeding events were bleeding on admission, fi-
brinogen under 60 mg/dL, thrombocytopenia un-
der 30 × 109/L and aPTT higher than 100 sec (10). 
This hypocoagulability is also found in vitro as 
demonstrated by thromboelastrometry of a series 
of patients with ACLF (11).
With regards to blood products use in patients 
with cirrhosis, there are no studies that support 
the administration of fresh frozen plasma to cor-
rect INR. However, the target of platelets should 
be above 50 to 60 × 109/L, fibrinogen above 100 
mg/dL and hemoglobin level above 7 g/dL. These 
recommendations apply for pre-procedure pro-
phylaxis in stable cirrhosis but are even more im-
portant in unstable cirrhotic patient with active 
bleeding (12).
Therefore, it has been demonstrated that pa-
tients with different stages of liver disease in the 
acute condition have a complex coagulopathy con-
current defects in pro-hemostatic and anti-hemo-
static pathways that may lead to both thrombosis 
and bleeding.
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SESSION 3—MUSCLE AND 
NUTRITION IN CIRRHOSIS
CONFERENCE 8: IMPACT OF 
SARCOPENIA—A MONTANO-LOZA
It was highlighted that sarcopenia is frequent in cir-
rhosis, with a prevalence reportedly ranging from 
40–70%, related to method of diagnostic test (1,2). 
The prevalence of sarcopenia is much higher that 
seen in other chronic conditions such as inflamma-
tory bowel disease or chronic kidney disease (3). 
The annual incidence of sarcopenia also outweighs 
that seen with ascites or variceal bleeding (1), but 
similar to that of hepatic encephalopathy (HE), al-
luding to the close relationship between the two.
Patients with cirrhosis experience twice as much 
annual skeletal muscle loss when compared with 
population norms (4). This may in part be related 
to malabsorption or reduced oral intake, chronic in-
flammation and hypogonadism (2). High ammonia 
levels may also promote muscle degradation (2).
Cross-sectional imaging is the current gold 
standard to quantify muscle mass; delineation 
of skeletal muscle with CT or MRI slices specifi-
cally at the L3 region has been found to have the 
best correlation with total body muscle mass and 
superior to analyzing just psoas muscle volume. 
Softwares can determine skeletal muscle volume 
and also distinguish subcutaneous and visceral 
adiposity. This is particularly advantageous in 
cirrhotic patients as other modes of quantifying 
muscle mass (such as with DEXA or body mass 
index) may be confounded by tissue edema or ex-
cess adiposity. Obtaining CT or MRI in every cir-
rhotic patient may however not be practical and 
hence other surrogates of sarcopenia are being 
evaluated, such as with point-of-care thigh ultra-
sound (5).
Specifically in cirrhosis, certain risk factors for 
sarcopenia have been identified and these include 
male sex, HE, C-reactive protein > 10 mg/L, and 
BMI < 25 kg/m2 (6).
Sarcopenia has been found to influence mortality 
both in the pre-transplant (7) and post-transplant 
setting (8), and is associated with increased risk of 
developing HE (9) and sepsis (7). Several studies 
have confirmed these findings; in a study by Mon-
tano-Loza et al. (7), sarcopenia was independently 
associated with increased pre-transplant mortality 
after adjusting for MELD, Child Pugh and sodium. 
Similar results were seen in a subsequent inter-
national study by Carey et al. (10) that included 
396 North American patients, as well as in other 
smaller studies (11). Particularly in low MELD pa-
tients (< 15), presence of sarcopenia may add to the 
discriminant value for prediction of mortality than 
compared with MELD alone (12). Pre-transplant 
sarcopenia has also been associated with increased 
post-transplant increased length of hospital stay, 
increased intensive care unit stay (13), and bacte-
rial infections (14). Post-transplant resolution of 
sarcopenia, though less well-studied, has also been 
found to influence overall survival positively (13).
Treatment options for sarcopenia are centred 
around interrupting pathways that lead to muscle 
protein degradation, and boosting those that pro-
mote muscle synthesis and proliferation. Practically 
speaking however, the two key aspects that clini-
cians should implement in daily practice include 
optimizing of nutrition, as well as encouragement 
towards exercise. Adequate protein (1.2–1.5 g/kg/
day) and calories (35–40 kcal/kg/day) should be 
consumed (15). Prolonged fasting for over 6 hours 
should be avoided, as this leads to accelerated 
breakdown of muscle (16). Hence patients should 
be advised to have a late-night high-protein snack 
prior to bedtime (16). Exercise should also be en-
couraged and may include a combination of aero-
bic and resistance training (17).
Finally, in cirrhotic men who are biochemically 
hypogonadal and sarcopenic, two clinical trials 
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have demonstrated that testosterone therapy im-
proved muscle mass, bone density and was well 
tolerated (18,19). A recent study has also shown 
that loop diuretic use in cirrhotic patients may 
have a direct impact on impairing skeletal muscle 
differentiation and associated with higher risk of 
muscle loss (20).
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CONFERENCE 9: NUTRITION AND 
CIRRHOSIS—M MERLI
The prevalence of malnutrition increases along 
with liver disease severity, and survival worsens 
with progressive malnourishment (1). Malnutri-
tion, used as a synonym of “under nutrition” may 
however go unrecognized. It should also encom-
pass the entity of sarcopenic obesity, given that 
the general prevalence of obesity and hence also 
the prevalence of cirrhosis and end-stage liver dis-
ease related to non-alcoholic fatty liver disease is 
increasing. Women have a physiologically lower 
muscle mass than men which may make it more 
difficult to appreciate a decrease in muscle mass, 
and hence sarcopenia may be less sensitive in iden-
tifying malnutrition in women in the way it does 
so with men. Women do however have more sub-
cutaneous fat (2). There is a close relationship be-
tween episodes of decompensation, malnutrition 
and sarcopenia as well as hepatic encephalopathy, 
bacterial infections and recurrent infections that 
lead to reduced survival in patients with cirrhosis.
All patients with cirrhosis should undergo a 
rapid nutritional screen with tools such as the Royal 
Free Hospital—Nutrition Prioritizing Tool or Liver 
Disease—Undernutrition Screening Tool. Those 
at highest risk of malnutrition are underweight 
(body mass index < 18.5 kg/m2) or Child Pugh C 
patients and should undergo a detailed nutritional 
assessment. A registered dietician should preferen-
tially carry out the nutritional assessment taking 
into account muscle function and muscle mass, as 
well as dietary intake. Body mass index (BMI) has 
a limited utility as a surrogate of malnutrition as 
weight may stay the same or even increase, despite 
dramatic changes in body composition in patients 
with water retention. The correlation between dif-
ferent body composition assessment tools is weak, 
and data is varied as different muscles have been 
explored utilizing different cutoff values (3). Even 
with current standards of evaluating sarcopenia, 
there has been no correction of age with the cut-
offs, despite the knowledge that muscle mass de-
creases with increasing age.
Survival rates improve when patients receive 
nutritional counselling from multi-disciplinary 
teams, when additional tools such as videos are 
used the impact is even increased. Physicians and 
patients alike should be aware of optimal meal 
calorie consumptions, with emphasis towards 
adequate protein intake. Ensuring adequate nu-
tritional intake may help to reduce episodes of 
hepatic encephalopathy (4). Late evening calorie 
supplementation is recommended to avoid peri-
ods of starvation as this promotes breakdown of 
fat and muscle (5). Physical activity should also 
be encouraged in patients with cirrhosis to pre-
vent sarcopenia (6). In obese patients, weight re-
duction could be considered, but protein intake 
should not be decreased. In patients with hepatic 
encephalopathy, protein restriction should not be 
prescribed and consumption of vegetal proteins 
and branched-chain amino acids may be useful.
There is evidence that in-hospital infections in-
crease after liver transplantation (LT) in patients 
with advanced liver disease and malnutrition (7,8). 
Sarcopenia pre-transplant may also be associated 
with post-LT mortality, intensive care stay and to-
tal hospital stay (7). Ideally, sarcopenia should be 
screened and targeted prior to LT. Early post-op-
erative enteral nutrition should be considered. In 
patients with HE, parenteral nutrition can be used 
if airway protection is a concern. Hyponatremia 
should also be carefully managed to avoid pontine 
myelinolysis. Sarcopenic obesity post-liver trans-
plant should also be considered, and most patients 
who put on weight post-LT do so with adipose 
rather than muscle mass (9). Metabolic problems 
have been seen to arise as soon as within a year 
post-transplant (9), which may be attributed to 
steroid use and immunosuppression. In the set-
ting of upper gastrointestinal bleeding, enteral nu-
trition should be withheld for 48–72 hours due to 
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the increased risk of increased portal pressure and 
variceal re-bleeding. Nutritional support may ac-
celerate resolution of hepatic encephalopathy and 
improve survival in patients with severe alcoholic 
hepatitis.
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CONFERENCE 10: HEPATIC 
ENCEPHALOPATHY AND DRIVING: A 
BUMPY ROAD—P WONG
Liver disease is one of the top 10 causes of death 
for Canadians (1) and affects up to one in four Ca-
nadians (2). Approximately 3,000 deaths a year oc-
cur from chronic liver disease and only about 500 
liver transplants are performed annually in Can-
ada. Deaths arising from motor vehicle accidents 
(MVA) is also a top 10 cause of mortality, with 
roughly 2,500 deaths annually (3).
Overt hepatic encephalopathy (OHE) refers to 
patients with clinically evident hepatic encepha-
lopathy (HE), usually those with West Haven HE 
grades II-IV. Roughly 30–40% of cirrhosis patients 
will develop OHE in their lifetime (4). Develop-
ment of OHE is a milestone event in a cirrhotic 
patient, and is a poor prognostic sign with sev-
eral series showing that > 50% of patients will die 
within 1 year after their first episode of OHE (5,6). 
Covert hepatic encephalopathy (CHE) refers to 
those patients with either minimal HE or Grade I 
West Haven criteria HE. Estimations of the latter’s 
prevalence are imprecise, with reported ranges of 
20–80% of patients being affected (4).
Several series using navigational simulators 
have shown that patients with minimal HE (MHE) 
have more frequent MVAs, road-edge excursions 
and centre crossings than patients without MHE 
(7,8). Patients with cirrhosis who are involved in a 
MVA are more likely to need hospitalization after 
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an accident and are at increased risk of mortality 
(9). Identification of patients suffering from CHE is 
needed for patient and public safety.
Multiple tests exist for the detection of CHE. Pa-
per and pencil tests have been the gold standard 
for years. The psychometric hepatic encephalopa-
thy score (ie. PHES) includes traditional tests such 
as the trail test, digit symbol test, serial dotting 
or line tracing tests and require training in order 
to administer the test properly (10). The test can 
be time consuming (45–60 minutes to administer) 
and is proprietary, requiring payment for its use. 
The MOCA (Montreal Cognitive Assessment) is 
desirable for its ease of administration and short 
duration, but lacks validation for hepatic encepha-
lopathy (11). More sophisticated neurophysiologic 
tests such as EEG, or auditory evoked potentials 
are poorly accessible and are better utilized under 
the supervision of a neurologist.
The last decade has seen advances towards more 
user friendly, rapid automated tests. The inhibitory 
control test is an inexpensive, non-copyrighted 
exam requiring minimal time to administer (15 
minutes) and does not require specialized training 
to use (12). The Stroop test is a smart phone appli-
cation freely downloadable and simple to admin-
ister, provided the patient is not afflicted by red 
green colour blindness (13). The animal naming 
test was also shown to have high predictive value 
to distinguishing those affected with CHE (14). All 
of these tests have been validated for CHE.
However, no single test can definitively distin-
guish safe from unsafe drivers in CHE. As a gen-
eral consensus, two tests should be administered 
to confirm the diagnosis.
Loss of autonomy is often significant for these 
patients and an empathetic approach when deliv-
ering this diagnosis and its implications is needed. 
Providing support, and enlisting the aid of family 
members in finding transportation solutions is cru-
cial. Although difficult, this message must be firm 
and non-negotiable. The stance from the CMPA 
and CMA is clear, that for patient and public safety 
reasons, physicians have a legal obligation to re-
port anyone that may be unsafe to drive (15). It is 
the Ministry of Transportation (MOT) that reserves 
the right to decide on further testing or revocation 
of one’s licence. A brief written statement should 
be provided detailing why you do not feel they 
should until their decision is finalized.
Alberta, Quebec and Nova Scotia have, “discre-
tionary” as opposed to “mandatory” reporting, but 
precedent has been set by the Highway Traffic Act 
in Ontario, in that the protection of public safety 
supersedes all else, even one’s patient physician 
relationship. Whether there exists a mandatory 
reporting condition (ie. Epilepsy) vs. a temporary 
condition (ie. Cervical spondylosis), physicians 
have a duty and legal obligation to immediately 
report patients that are unsafe to drive. This princi-
ple has been upheld repeatedly in Canadian courts 
(16).
In conclusion, CHE is underdiagnosed and is 
clearly associated with increased risk of MVAs. For-
malized testing for CHE is now automated, with 
high likelihoods of detection, and ease of adminis-
tration for office use. Failure to report drivers that 
continue to drive when they should not is unsafe 
and negatively erodes confidence in the medical 
profession. Physicians have a legal responsibility 
to report and fulfill their statutory duty towards 
public safety.
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CONFERENCE 11: CHALLENGES 
WITH LIVER TRANSPLANTATION: 
PALLIATIVE CARE—P TANDON, A 
BRISEBOIS
As defined by the World Health Organization, 
palliative care is “the active total care of patients 
whose disease is not responsive to curative treat-
ment”. An approach to care using palliative prin-
ciples improves “the quality of life of patients and 
their families facing problems associated with life-
threatening illness, through the prevention and 
relief of suffering by means of early identification 
and impeccable assessment and treatment of pain 
and other problems, physical, psychosocial and 
spiritual” (1,2). In addition to symptom manage-
ment, advance care planning (ACP) is a central 
component of care using palliative principles. ACP 
is defined as a process that supports adults at any 
age or stage of health in understanding and shar-
ing their personal values, life goals and preferences 
regarding future medical care (3). This integrated 
approach to care has already demonstrated signifi-
cant benefits in other chronic disease populations 
(4–6). These include improved patients’ symp-
toms, a higher likelihood of dying at home, more 
focused ACP, better psychosocial health, reduced 
healthcare utilization and higher patient/family 
satisfaction. Data in cirrhosis is emerging. In a re-
cent study of delisted liver transplant candidates 
(7), the integration of routine palliative care con-
sultation was associated with a shorter duration 
to “do not resuscitate” (DNR) status, a decrease in 
ICU stay time and a positive family response to the 
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incorporation of palliative care consults (7). Impor-
tantly, patient mortality was not hastened by this 
intervention. Palliative care has also been shown 
to improve health related quality of life (HRQoL) 
and decrease healthcare utilization in cirrhosis (8).
Rates of palliative care consultation remain low. 
Recent studies have reported palliative care con-
sultation in 11% of patients ineligible for trans-
plantation (9,10), with 90% of referrals taking place 
within 72 hours of death (10).
There are several recognized barriers that con-
tribute to this underutilization. Prognostication 
and prediction of the time course of death and 
disease trajectory is challenging in these patients 
(11). Patients with more compensated or well 
controlled cirrhosis may not appear as ill as they 
really are and severe decompensation can occur 
rapidly (12,13). Few clinicians routinely screen for 
symptoms such as pain or muscle cramps in clini-
cal practice, or feel comfortable managing these 
symptoms in the setting of cirrhosis. This leads 
to underestimation of symptom burden and un-
der treatment (14). Recent reviews of cirrhosis do 
not include symptom management in their algo-
rithms (15–17). Lastly, there is a common miscon-
ception about the role of palliative care as being 
limited to the last few days of life (18). It is vital to 
remember that palliative care is not simply about 
quelling the inevitable tide of death, but more 
importantly, hinges upon enriching the patient 
life that yet remains. Palliative principles are ap-
plicable to patients with years of life still left to 
live, but with serious illness and high symptom 
burden.
While it has been suggested that specific symp-
toms of decompensated liver disease, such as asci-
tes or HE could be used as potential triggers for a 
palliative care consult (19), ideally, palliative care 
principles and end of life planning should be insti-
tuted in some capacity in all patients with cirrhosis 
and certainly prior to the onset of HE. This early 
integration of ACP can be applied by all health 
care practitioners and does not require consulta-
tion from trained palliative care health practitio-
ners who may be needed in more severe cases or 
at the end of life.
The burden of cirrhosis is not only on patients. 
Informal caregivers are an essential component of 
the medical management of chronically ill patients 
and are vital to the financial viability of North 
American health care (20,21). Although not stud-
ied directly in cirrhosis, patient outcomes improve 
with the involvement of informal caregivers (22). 
Their involvement leads to less complications and 
fewer hospital admissions (23–26). Informal care-
givers are responsible for much of the care pro-
vided to patients with cirrhosis, taking a major role 
in medication management and the administration 
of palliative care (24). In their 2012 study, Rakoski 
et al. found that one third of patients with cirrho-
sis identified an informal caregiver (24). These 
patients required twice the number of informal 
caregiving hours per week when compared with 
an age matched population. Caregiver stress may 
be considered a trigger for palliative care consul-
tation. Specialized palliative care services have 
been associated with both short- and long-term 
caregiver outcomes (27). Although not formally in-
vestigated in the setting of cirrhosis and HE, other 
strategies for easing caregiver burden are becom-
ing more well-established and should be trialed in 
patients with cirrhosis. Potential interventions in-
clude multidisciplinary care with a social worker 
and a psychologist as well as focused family psy-
choeducation (23,28). Targeted interventions to 
increase caregiver effectiveness, such as telephone 
interventions and caregiver support groups have 
been effective in other populations (29–31) and 
may also prove to be of benefit in HE. A short 
program of mindfulness and supportive group 
therapy proved beneficial for the management of 
caregiver burden in a recent study in patients with 
cirrhosis (32).
In summary, the routine use of palliative prin-
ciples has the potential to optimize effective and 
comprehensive management of patients with cir-
rhosis and their caregivers. The number of studies 
evaluating this areas is growing steadily over time.
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SESSION 4—CRITICAL CARE 
AND LIVER TRANSPLANT IN 
THE ACLF PATIENT
CONFERENCE 12: ACUTE ON CHRONIC 
LIVER FAILURE AND CRITICAL 
CARE—J WENDON
It is difficult to predict which patients will ben-
efit the most from admission to critical care unit 
(CCU), a resource with limited availability and 
high resource utilization. Key CCU benefits in-
clude supporting organ failures and providing 
time for potential organ recovery. Within criti-
cal care, outreach is an important aspect that al-
lows identifications of patients who may benefit 
from CCU admission early in the disease course. 
Early identification of patients is essential, both 
for patients with and without liver disease (1,2). 
The later a patient is identified to be critically 
ill, the higher the chance of CCU admission and 
the higher the mortality rate is. Time to antibi-
otic administration is the key factor affecting 
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mortality. During the first 48 hours, broad-
spectrum antibiotics should be used and then 
narrowed after 48 hours. Patients with chronic 
liver disease also have higher mortality when 
admitted to the ICU compared with patients 
with other major chronic comorbidities such as 
stage 5 chronic kidney disease (3,4). Validated 
pronostic indices include the CLIF-organ failure 
score system and the SOFA score (5). Validated 
cutoffs for futility include SOFA score or 13 or 
more and blood lactate levels or 4 mmol/L or 
more that are associated with a mortality over 
90% (6). Mortality rises with increasing num-
bers of failing organs (7).
Sepsis is a major actor in acute-on-chronic liver 
failure (ACLF) patients during which patients 
have inadequate immune responses, with exces-
sive systemic inflammation in some and dysfunc-
tion of immune mechanisms in others (8,9). The 
frequent occurrence of invasive aspergillosis in 
patients with severe alcoholic hepatitis, associated 
with increased mortality is an example of this (10).
In ACLF, patients have a hyperdynamic state. 
Fluid balance is delicate in this population. Tools 
to guide volume management include mean ar-
terial pressure, mixed venous blood saturation, 
central venous pressure, intra-abdominal pres-
sure, ultrasound monitoring of the inferior vena 
cava and heart cavities (11). Patients who are 
volume depleted will be overconstricted while 
those who are overloaded will develop organ 
congestion. Both situations lead to ischemia. The 
presence of a flow murmur may signify outflow 
tract obstruction and fluid overload. B-type na-
triuretic peptide (BNP) can help separate cirrhot-
ics who are volume overloaded from those who 
are underfilled. Regarding fluid resuscitation, 
balanced salt solutions result in less hyperchlo-
remia, greater normal bicarbonate levels, and less 
adverse renal events. Hypercholeremic acidosis 
carries a high rate of mortality in the general CCU 
population (12).
Cirrhotics with septic shock have a trend toward 
better survival with terlipressin compared with 
norepinephrine but develop more adverse events 
including myocardial, visceral and peripheral isch-
emia (13). Hydrocortisone does not affect mortality 
in ACLF patients. Profound shock and vasopres-
sor requirement during CCU admission may lead 
to ischemic cholangiopathy even in patients with-
out underlying liver disease (14). Albumin is com-
monly utilized in the CCU and has antioxidant and 
hemostatic effects. It is important in drug transport 
and has survival benefits in spontaneous bacterial 
peritonitis, but not in other bacterial infections in 
cirrhotic patients (15–17).
Aside from usual indications, renal replacement 
therapy is used in patients with liver failure to 
manage hyponatremia, hypercholeremia, acidosis, 
hyperammonemia and encephalopathy, and fluid 
overload (18). In terms of encephalopathy, intuba-
tion may be required. Once intubated, avoid excess 
sedation, utilize a feeding tube to provide nutri-
tional support, and provide thromboprophylaxis. 
Extracorporeal membrane oxygenation (ECMO) 
needs further assessment in the setting of liver dis-
ease, mainly in acute liver failure.
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CONFERENCE 13: ARTIFICIAL LIVER 
SUPPORT—SL NYBERG
Artificial liver support devices have been studied 
for many years. Their use has shown improve-
ments in hepatic encephalopathy but has not yet 
shown an improvement in survival. Devices for 
liver support are either artificial (hemofiltration, 
plasma exchange, or albumin-based) or cell-based 
(human cell lines or pig hepatocytes).
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The Molecular Adsorbent Recycling System 
(MARS) uses albumin within the circuit to remove 
albumin bound toxins along with charcoal and ex-
change resin columns. In 2015, MARS was used 
over 3,000 times worldwide. No survival benefit 
was seen with MARS in acute-on-chronic liver fail-
ure patients but improvements were seen in biliru-
bin, creatinine, and encephalopathy grade (1). The 
DIALIVE liver support system also uses albumin 
exchange to remove albumin bound toxins, but 
contains an endotoxin removal system as well. It 
is currently being used in clinical testing. The Ex-
tracorporeal Liver Assist Device (ELAD) has been 
studied extensively and utilizes C3A hepatic cells in 
a plasma circuit. In a recent study looking at efficacy 
in acute alcoholic hepatitis patients, no overall sur-
vival benefit was seen when using ELAD compared 
with standard medical therapy. However, subgroup 
analysis showed that patients less than age 50 with 
low creatinine and INR but high bilirubin had sig-
nificantly higher survival in the ELAD treatment 
group compared with the non-ELAD treatment 
group (2). Follow up study of alcoholic hepatitis pa-
tients who were younger than 50 years of age with 
low creatinine and INR treated with ELAD versus 
standard medical therapy did not show a survival 
benefit with this device.
The Mayo Bioartificial Liver Spheroid Reservoir 
(SRBAL) is similar to MARS but the charcoal and 
resin systems are replaced with a pig hepatocyte 
reservoir maintained in a spheroid configuration. 
SRBAL showed significantly improved survival 
in three large recent animal studies (3–5). Future 
of liver cell therapies would involve a readily 
available supply of human hepatocytes. Geneti-
cally engineered animals can be used as incuba-
tors and this has been done in mice and pigs (6). 
Fumarylacetoacetate hydrolase (FAH) deficient 
pigs had FAH positive hepatocytes transplanted 
into their livers. By 12 months, the liver is com-
pletely replaced with FAH positive hepatocytes. 
Human hepatocytes can be transplanted into pig 
livers using the principle of fetal tolerization. Hu-
man hepatocytes are injected into fetal pigs prior 
to their development of an immune system (7). 
Currently, double knock-out pigs are used and 
hepatocytes are transplanted early in gestation. 
This has led to improvement in human cell en-
graftment and will hopefully lead to trials in hu-
man subjects.
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CONFERENCE 14: PERIOPERATIVE 
MANAGEMENT DURING LIVER 
TRANSPLANTATION FOR ACUTE 
ON CHRONIC LIVER FAILURE—FM 
CARRIER
Acute-on-chronic liver failure (ACLF) is an entity 
that requires the presence of organ dysfunction as 
defined by the CLIF (Chronic Liver Failure) Con-
sortium organ dysfunction score in a patient with 
chronic liver disease (1). Grade 1 ACLF is defined 
by severe acute kidney injury (AKI), one organ 
dysfunction plus either mild AKI or grade 1 or 2 
hepatic encephalopathy (HE), or mild AKI plus 
grade 3 or 4 HE. Grade 2 ACLF implies two organ 
dysfunctions and grade 3 ACLF implies three or 
more organ dysfunctions. The greater the ACLF 
grade, the higher the mortality is without liver 
transplantation (LT) with an observed 28-day mor-
tality over 60% in grade 3 ACLF and a 7-day mor-
tality of 100% with five for more failing organs (2). 
Cohort studies showed that ACLF patients who 
undergo LT have 1-year survival rates from 60% to 
84% (3–7). In one study from France, ACLF grade 3 
patients who underwent LT had similar 1-year sur-
vival to those without ACLF (83.6% vs 90%, hazard 
ratio = 1.75 [0.82–3.71]) and also had a major sur-
vival advantage over patients with ACLF who did 
not receive LT (83.6% vs 7.9%, p < 0.0001).
Predictors of postoperative mortality in ACLF 
include age, elevated physiological scores (SOFA, 
CLIF-C ACLF score), higher ACLF grade, develop-
ment of the acute respiratory distress syndrome 
(ARDS) and presence of persistently elevated lac-
tate levels. ACLF patients who undergo LT gen-
erally have very high Model for End-Stage Liver 
Disease (MELD) scores and are on organ support 
such as vasopressors, mechanical ventilation and 
renal replacement therapy (RRT) compared with 
non-ACLF LT recipients (3,4). Hemodynamically, 
they have a hyperdynamic state (high cardiac 
output, vasodilation, hypotension, splanchnic va-
sodilation and renal vasoconstriction) more pro-
nounced than other end-stage liver disease (ESLD) 
patients, which makes their anaesthetic manage-
ment delicate. Intraoperative fluid management 
in all ESLD patients undergoing LT is still contro-
versial, but, a restrictive strategy seems to result in 
less bleeding and less pulmonary complications 
(8). Studies have suggested ESLD patients are va-
sopressin depleted similar to patients with septic 
shock and a preferential use of vasopressin-de-
rived vasopressor might be associated with a lower 
portal pressure and a lower postoperative serum 
creatinine level. Overall, restrictive fluid manage-
ment and use of vasopressin derivatives may be 
beneficial during LT.
ACLF patients undergoing LT have profound 
derangements in coagulation that include throm-
bocytopenia and coagulation factors deficits (9). 
However, regular coagulation tests are not a 
good reflect of global coagulation in patients with 
chronic liver disease and do not predict bleed-
ing accurately (10). Factors affecting bleeding 
during LT include disease severity and volume 
management. Thromboelastography (TEG) can 
help predict bleeding (11,12) and reduce the use 
of red blood cells and plasma during LT (13,14). 
RRT use during LT may also improve outcomes 
in ACLF patients (15). All the aforementioned 
therapeutic approaches are based on low-quality 
evidence. Further evidence is required for most 
of them and criteria for ACLF patient selection 
for LT in this complex situation require further 
studies.
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CONFERENCE 15: LIVER 
TRANSPLANTATION IN ACUTE 
ON CHRONIC LIVER FAILURE: 
CHALLENGES WITH PREDICTING 
FUTILITY—CJ KARVELLAS
Acute-on chronic liver failure is a syndrome de-
fined by acute decompensation of chronic liver 
disease with organ failures and high short-term 
mortality (1,2). In the absence of liver transplant 
(LT), acute-on-chronic failure (ACLF) grade 
discriminates between patients with different 
prognostic categories (2). As the ACLF grade 
increases, 28-day and 90-day mortality also in-
creases. The Chronic Liver Failure Consortium 
(CLIF-C) ACLF Score incorporates age and white 
blood cell count along with CLIF-C organ failure 
score [bilirubin, creatinine, hepatic encephalopa-
thy (HE), INR, blood pressure, and PF ratio] (3). 
Higher CLIF-C ACLF scores on admission to the 
intensive care unit (ICU) correspond to greater 
164     Canadian Liver Journal Fall 2019
V Dong, M Gosselin, N Jagarlamudi, et al
mortality. Patients who improve their ACLF 
grade at 72 hours post-admission have a natural 
history corresponding to the new ACLF grade at 
day 3 (4).
Within Canada, 3,000 to 4,000 patients die a 
year from liver disease and only about 500 LT 
procedures are performed a year. Allocation cur-
rently is based on the MELD sodium (MELD-Na) 
score resulting in the sickest patients receiving 
a transplant first. Factors that impact LT utility 
in ACLF patients include medical comorbidities, 
sarcopenia, severity of organ dysfunction, and 
donor factors. If patient survival is expected to 
be 50% or less at 5 years, it is of widespread ac-
ceptance that LT will be futile (5). Medical con-
traindications include body-mass index greater 
than 40, portopulmonary hypertension with 
mean pulmonary arterial pressure greater than 
45 mmHg, left ventricular ejection fraction less 
than 50%, and severe underlying lung disease. 
Sarcopenia has an impact on increasing length of 
hospital and intensive care unit stay post LT, but 
not survival (6).
Severity of illness scores like Sequential Organ 
Failure Assessment (SOFA) and CLIF-C ACLF 
scores have more utility in discriminating be-
tween patients dying on the waitlist (differentiat-
ing waitlist mortality) than those with acceptable 
results post LT. Advancing age or incremental 
increase in age is associated with 90-day mortal-
ity post-LT whereas SOFA is not (7). The more or-
gan failures a patient has while in the intensive 
care unit (ICU) while awaiting a LT, the greater 
the chance of mortality within 30 days while on 
the waiting list (8). Other prognostic variables for 
ICU-mortality include increasing age and SOFA 
and lactate levels at 48 hours (7). The number of 
organ failures did not have as much of a signifi-
cant effect on post-LT survival (8,9). This may be 
due to careful selection of patients with ACLF in 
terms of LT suitability.
Aside from patient survival post-LT, other im-
portant end-points include length of ICU or hos-
pital stay and post-LT complications, such as 
delirium. Even though ACLF grade did not signifi-
cantly affect post-LT survival, it did impact length 
of ICU and hospital stay post-LT in the cohort by 
Artru et al. (9). Cost of hospitalization increases. 
The Perioperative Survival Outcomes Following 
Liver Transplantation (P-SOFT) score incorporates 
both donor and recipient variables to predict sur-
vival post-LT (10).
Patients denied LT rarely receive adequate palli-
ative care or appropriated management such as do 
not resuscitate orders or palliative care referral (11).
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or ‘rescue’ LT, remains hotly contested with strong 
opinions expressed both for and against (2,3).
The nexus of Alcohol-Use Disorder (AUD) and 
Alcohol-associated Liver Disease (ALD).
In my opinion, the controversy surrounding 
‘Rescue LT’ for severe AH’ stems from the com-
plicated nexus of AUD and ALD. Our conflicted 
interpretation of AUD as either a disease or a 
‘disorder of choice’ has meant that there is a 
bedrock of opinion that considers patients with 
AUD to be personally responsible for their pre-
dicament and therefore less ‘deserving’ of scare 
resources such as a liver allograft (4). This con-
tention, which appeared to have lost support has 
returned with the advent of LT for patients with 
severe AH. Recently, Solga et al. have proposed 
explicitly that ALD patients should have less pri-
ority, stating that ‘The Organ Procurement and 
Transplantation Network could review whether 
MELD for MELD allocation could be prioritized 
for patients with chronic liver disease ahead of 
those with AH’ (5). For a contrary view, I refer 
you to Benjamin’s masterful deconstruction of 
these arguments (6).
A second source of confusion relates to outcome 
of AUD after LT. Irrespective of the stringency of 
selection, some ALD patients will return to drink-
ing after LT (7). The transplant community remains 
conflicted as to whether this behaviour constitutes 
a failure of LT, or is simply the natural history 
of AUD.
Finally, there is concern that public support for 
donation to LT will decline if more ALD patients re-
ceive LTs. Evidence to support this contention is slim.
LT for ALD: a historical perspective(8).
In 1984, the NIH held a consensus conference 
regarding LT. This was a turning point that es-
tablished LT was a viable therapy rather than 
experimental. However, within the discussion, 
Dr. Steven Schenker asserted that ALD patients 
would be ‘rarely suitable’ for LT. This position 
had changed by 2003. In that year, the AASLD and 
the AST organized a conference entitled ‘Minimal 
criteria for placement of adults on the LT waiting 
list’. At the conference, it was reported there the 
6-months abstinence requirement (‘the 6-month 
rule’) was the norm in US transplant centres when 
assessing the suitability of patients with ALD. As a 
consequence, the interdiction on LT for AH, which 
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8. Thuluvath PJ, Thuluvath AJ, Hanish S, 
Savva Y. Liver transplantation in patients 
with multiple organ failures: Feasibility and 
outcomes. J Hepatol. 2018;69(5):1047–56. 
https://doi.org/10.1016/j.jhep.2018.07.007. 
Medline:30071241
9. Artru F, Louvet A, Ruiz I, Levesque E, Labreuche 
J, Ursic-Bedoya J, et al. Liver transplantation 
in the most severely ill cirrhotic patients: A 
multicenter study in acute-on-chronic liver 
failure grade 3. J Hepatol. 2017;67(4):708–15. 
https://doi.org/10.1016/j.jhep.2017.06.009. 
Medline:28645736
10. Rana A, Hardy MA, Halazun KJ, Woodland 
DC, Ratner LE, Samstein B, et al. Survival 
outcomes following liver transplantation 
(SOFT) score: a novel method to predict patient 
survival following liver transplantation. Am 
J Transplant. 2008;8(12):2537–46. https://
doi.org/10.1111/j.1600-6143.2008.02400.x. 
Medline:18945283
11. Poonja Z, Brisebois A, van Zanten SV, Tandon 
P, Meeberg G, Karvellas CJ. Patients with 
cirrhosis and denied liver transplants rarely 
receive adequate palliative care or appropriate 





CONFERENCE 16: CONTROVERSIES 
IN LIVER TRANSPLANTATION: 
ALCOHOLIC HEPATITIS—MICHAEL R. 
LUCEY
Introduction.
Whereas liver transplantation (LT) for end-stage 
liver disease due to alcohol has become standard of 
care, such that alcohol-related liver disease (ALD) 
has become the most frequent indication for liver 
transplantation in the US (1), LT for patients with life-
threatening alcoholic hepatitis (AH) not responding 
to medical treatment, sometimes referred to as early 
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6 weeks, persisted. However, even this limitation 
has now been breached. In 2017, EASL published 
it’s guideline on ALD, and stated that “the selec-
tion of patients with AUD should not be based on 
the six-month criterion alone”. Additionally, “early 
LT should be proposed to a minority of patients 
with severe AH not responding to medical therapy 
after a careful selection process”.
Selection of ALD patients for LT.
It would be wrong to claim that there is a consen-
sus in the US at present about rescue LT for AH, 
and the ‘six-month rule’ still has its adherents (9). 
Furthermore, it is endorsed by many payers and 
transplant centres. However unwavering adher-
ence to the of the 6-month rule leads to unwanted 
as well as wanted consequences. Its advocates 
point to out that the ‘six-month rule’ is associated 
with a modest reduction in risk of ‘any use’ of 
alcohol after transplant; and it is simple to ap-
ply. On the other hand, it is subject to manipula-
tion and misinformation. It admits patients who 
will relapse after transplantation while excluding 
some patients who will not drink after transplan-
tation. The alternative to a concrete abstinence 
rule is a psychosocial assessment that considers 
the risk of relapse as one of the elements con-
tributing to the patient’s ability to protect a liver 
allograft.
Alcohol use by ALD patients after LT.
Even in cohorts selected by stringent criteria, re-
turn to alcohol use by some ALD recipients ap-
pears inevitable (7). It is important to distinguish 
between so-called ‘slips’, minor or transient use, 
often followed by renewed efforts toward ab-
stinence from harmful sustained consumption, 
which is referred to as a relapse (7). Relapses are 
associated with all the injuries that occur to re-
lapsing AUD patients in other circumstances: 
pneumonia, pancreatitis, delirium tremens, de-
pression, marital breakdown, drunk driving, work 
absences. Furthermore, harmful drinking leads to 
accelerated fibrosis of the allograft. Graft loss due 
to ALD is rare in the first 5 years, but occurs at 10 
years in heavy drinkers.
Rescue LT for AH.
To date the most influential (and iconoclastic) pa-
per on LT for AH was the combined Franco-Bel-
gian report of a pilot study of 26 patients who had 
failed medical treatment (10). All were approved 
following stringent psychosocial assessment. In 
the initial report, the survival of the pilot cohort 
was compared with 26 matched historical control 
subjects, and an unequivocal benefit was observed. 
Dr. Mathurin and colleagues are in the process of 
completing a prospective study with a greater 
number of subjects and contemporaneous con-
trols. More, recently a consortium of 12 US trans-
plant centres called ACCELERATE have published 
retrospective account of rescue LT for severe AH 
(11). The median interval from the last drink was 
55 days, range 36–91. The mean MELD score at LT 
was 39. The patient and graft survival in the first 
3-years post LT was excellent (94% at 1-year) and 
similar to that observed in contemporaneous ALD 
patients with established abstinence.
In Mathurin’s small cohort, relapse to alcohol 
was infrequent. In the US study, in the first 3 years, 
16% of patients experienced relapse, while another 
17% reported slips.
Given these data, one may ask rhetorically: 
why is rescue LT not standard of care for life-
threatening AH? In answer, I would say that 
we are at a turning point. However, as outlined 
about, there continues to be confusion about the 
endpoints when considering outcome of LT in 
patients with AUD in general, and AH in partic-
ular. In the future, we need prospective studies 
that include clarity about selection, and manage-
ment of AUD both in the lead up to and after LT. 
We also hampered by lack of definitive American 
data. Finally, we should not ignore the dynam-
ics of transplantation, the need to engage all the 
stakeholders, while maintaining vigilance against 
promoting stigma.
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CONFERENCE 17: ACUTE KIDNEY 
INJURY IN CIRRHOSIS—F WONG
Acute kidney injury (AKI) is a commonly en-
countered complication in patients with decom-
pensated cirrhosis. It is defined by an increase 
of 50% in serum creatinine from baseline that 
is presumed to have occurred within the past 7 
days (Table 1). Hepatorenal syndrome (HRS) 
is a potentially reversible syndrome that occurs 
in patients with cirrhosis, ascites and liver dys-
function, consisting of impaired renal function, 
marked abnormalities in cardiovascular function, 
and intense over-activity of the endogenous vaso-
active systems. The most recent diagnostic crite-
ria define it as Stage 2 or 3 AKI in those patients 
with cirrhosis and ascites with no improvement 
in serum creatinine (decrease of creatinine to ≤ 
0.3 mg/dl of baseline) after at least 48 hours of 
diuretic withdrawal and volume expansion with 
albumin. In addition, there should be no recent 
use of nephrotoxic agents and no significant pro-
teinuria or hematuria, urine casts along with the 
absence of shock (1).
Several mechanisms lead to the evolution of re-
nal dysfunction and injury in cirrhosis resulting in 
AKI.
Obstruction to portal flow secondary to cirrho-
sis, increased translocation of gut bacteria and bac-
terial products into the portal circulation and shear 
stress on portal vessels have vasodilatory effects 
on the splanchnic circulation. These mechanisms 
interact and amplify the circulatory dysfunction. 
Angiogenesis is also increased in the mesenteric 
circulation which results in an increased capaci-
tance of the splanchnic circulation. This leads to 
an increase in the total capacitance of total circu-
lating volume and leads to a reduction in effective 
arterial blood volume. This results in activation 
of various compensatory vasoconstrictor mecha-
nisms in an attempt to reduce the circulatory ca-
pacitance. The kidneys are particularly sensitive to 
the vasoconstrictive effects of these systems which 
ultimately leads to reduced renal blood flow and 
glomerular filtration. Sodium retention is the com-
pensatory mechanism of decreased glomerular fil-
tration rate and decreased renal blood flow. It is the 
Table 1: Diagnosis of renal dysfunction in cirrhosis
Parameter Definition
Baseline SCr Stable SCr ≤ 3 months
If not available, a stable SCr closest to the 
current one
If no previous SCr at all, use admission SCr
Definition of 
AKI
↑ in SCr ≥ 26.5 μmol/l (0.3 mg/dL) ≤ 48 
hours, or
↑ 50% from baseline
Staging Stage 1: ↑ SCr ≥ 26.4 μmol/L (0.3 mg/dL) or 
↑ SCr ≥ 1.5–2.0 × from baseline
Stage 2: ↑ SCr > 2.0–3.0 × from baseline
Stage 3: ↑ SCr > 3.0 × from baseline, or SCr 
≥ 352 μmol/L (4.0 mg/dL) with an acute 
↑ of ≥ 26.4 μmol/L (0.3 mg/dL), or Initia-
tion of renal replacement therapy
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physiological response to increase the circulatory 
volume. The bacterial translocation includes bacte-
ria, their DNAs and bacterial products, collectively 
known as pathogen-associated molecular patterns 
(PAMPs). These together with injured hepatocytes 
and their necrotic products known as damage-as-
sociated molecular patterns (DAMPs) also result 
in increased infectious and non-infectious activa-
tion of systemic inflammation and leads to produc-
tion of inflammatory cytokines (2). In addition to 
the circulatory mechanisms, DAMPs and PAMPs, 
when filtered by the glomeruli, cause direct tubular 
damage in the kidneys and changes in renal micro-
vasculature (3).
Whilst a lot of research has been done in the field 
of biomarkers in renal dysfunction other than our 
current standard of using serum creatinine, these 
are not readily available to most practicing clini-
cians. Those showing promise include NGAL and 
IL-18 (4,5). An increasing number of positive bio-
markers suggests a diagnosis of acute tubular ne-
crosis (ATN) as the cause of AKI (6).
Once diagnostic criteria are fulfilled, the cause 
of renal failure must be determined and intrin-
sic causes excluded. HRS remains a diagnosis of 
exclusion. The current treatment algorithm em-
phasizes the importance of appropriate volume 
expansion with albumin (1 g/kg, maximum 100 
g/day for 2 days) prior to diagnosis of HRS. On 
top of its quantitative decrease, albumin has qual-
itative defects in chronic liver disease. Albumin 
therapy has several mechanisms of action that 
include antioxidant effects and immunomodula-
tion (7). Once HRS is diagnosed, vasoconstrictor 
treatment is the next step with renal replacement 
therapy being reserved for non-responders that 
are suitable transplant candidates (8). Terlipressin 
is the most studied drug in the treatment of HRS 
and responders have increased survival (9,10) and 
has similar efficacy than norepinephrine that re-
quires intensive care unit monitoring (11). Liver 
transplantation is the definitive treatment for 
AKI not responding to therapy. The optimal tim-
ing and the indication for combined liver-kidney 
transplantation remains difficult to define. Early 
referral is key (12).
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90% when given for 12 or 24 weeks (1). In the SO-
LAR-2 trial with the same patient population and 
study drugs, the results were comparable in CPT B 
patients (SVR 87–96%), but were inferior in CPT C 
patients (SVR 78–85%) (2). HCV becomes increas-
ingly difficult to treat once a patient has an episode 
of DAA failure. Selecting the best therapy for max-
imizing sustained virologic response (SVR) hence 
becomes crucial. After SVR, most patients had im-
provements of one to five points in their MELD 
score, but a certain minority showed deterioration. 
Rates of serious adverse events were higher in 
CPT C patients with around one third. It is hard to 
differentiate drug toxicity from the natural history 
of advanced cirrhosis. Current evidence supports 
the use of ribavirin (weight-based dosing) in im-
proving SVR rates in certain patient populations, 
particularly those with genotype 3 and advanced 
cirrhosis as evidenced by the ASTRAL-4 trial (3). 
Moderate anemia is a common side-effect of riba-
virin treatment.
Drug combinations with protease inhibitors 
such as paritaprevir, ritonavir, ombitasvir and 
dasabuvir is safe and very effective in patients 
with CPT A cirrhosis and genotype 1 infection 
with SVR rates of 89–100% (4). However, cases of 
hepatic decompensation and death in CPT B and 
C patients have led to an absolute contra-indica-
tion of PIs in these patients. Direct drug toxicity 
has also been reported in PIs-free regimens (5), 
but overall the experience with these drugs is very 
reassuring.
Real world data have shown that DAA regimens 
are very safe in CPT A patients, but that decom-
pensation occurs in about half of others (6). Predic-
tors of decompensation were serum albumin < 35 
g/L, MELD score over 14 and genotype 3 patients. 
The same albumin threshold of 35 and age over 65 
were identified in another cohort (7). In the data 
from the English expanded access program, the 
mid-term survival without adverse events in CPT 
C patients was very low, which questions the use 
of DAA in these patients (8).
There still is some doubt as to how much DAA 
regimens can make it possible to avoid liver 
transplantation in patients with decompensated 
cirrhosis. The concept of the MELD purgatory 
has been brought up to reflect the situation of pa-
tients with moderate biochemical improvements, 
but ongoing clinical problems without access to 
transplantation. In a European cohort, delisting 
was possible mostly in patients with a baseline 
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CONFERENCE 18: TREATMENT OF HCV 
IN PATIENTS WITH DECOMPENSATED 
CIRRHOSIS—JJ. FELD
Hepatitis C viral infection (HCV) has become a 
much easier disease to treat for the majority of 
those affected with the advent of direct-acting anti-
virals. However, it does remain a challenge in those 
with decompensated cirrhosis. Delaying treatment 
after liver transplantation (LT) is safer and results 
in higher sustained virologic response (SVR) rates, 
but makes LT necessary, exposes patients to drug-
drug interactions (DDIs) and to the risk of fibros-
ing cholestatic hepatitis. The current goals of care 
for this patient group are to i) maximize treatment 
response, ii) avoid harm, and iii) to decide when to 
and when not to treat.
In the SOLAR-1 trial in patients with Child-Pugh-
Turcotte (CPT) B and C cirrhosis and infection with 
genotype 1 and 4, the combination of sofosbuvir, 
velpatasvir and ribavirin led to SVR rates around 
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MELD score below 16 (49%), but rare in patients 
with baseline MELD 16–20 (18%) and over 20 
(15%) (9). The BE3A score has been proposed to 
identify patients using the following criteria: 
Body-mass index < 25, absence of Encephalopa-
thy, absence of Ascites, Albumin > 35 g/L and 
ALT > 60 IU/L. Those with a score of 4 or 5 were 
the most likely to turn out CPT A after 36 weeks 
of follow-up. This score performs probably best 
at identifying those who will not benefit for treat-
ment before transplantation.
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